The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Abstract
The non-benzodiazepine GABA A receptor modulators (‘Z-drugs’) — zaleplon, zolpidem, zopiclone and eszopiclone — have become the accepted treatments for insomnia where they are available. However, recent randomized, placebo-controlled trials suggest that, for these drugs, there may be particular efficacy and tolerability profiles and distinct clinical outcomes in specific patient populations. This is particularly apparent when hypnotic/ selective serotonin reuptake inhibitor co-therapy is used to treat patients with co-morbid insomnia and psychiatric disorders, as patient recovery appears to be accelerated and enhanced by some drugs but not others. Emerging evidence of why this should be the case is that these hypnotic drugs may differ significantly from each other in their pharmacodynamic and pharmacokinetic profiles. Functional selectivity for specific GABA A receptor subtypes may determine each drug’s clinical attributes, while the pharmacokinetic characteristics of Z-drugs also determine to a large extent how they perform in the clinic. For example, activity at GABA A alpha 1 receptor subtypes may be associated with sedative effects, whereas activity at alpha 2 and alpha 3 receptor subtypes may be associated with anxiolytic and antidepressant effects. In summary, the distinct clinical outcomes of zaleplon, zolpidem, zopiclone and eszopiclone may be explained by each drug’s unique GABA A receptor subunit selectivity and pharmacokinetic profile. Further investigation of GABA A receptor subtype effects would help to increase understanding of current hypnotic drug effects, while knowledge of each drug’s specific binding profile should enable clinicians to tailor treatment to individual patient’s needs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is clinical evidence for the antidepressant effects of subtype selective GABAAR compounds as eszopiclone, a positive GABAAR modulator with postulated selectivity for α2/α3GABAARs [138], has a synergistic effect when given in combination with fluoxetine in patients with depression and insomnia [139].”
From An emerging circuit pharmacology of GABAA receptors (2018) · cites this paper as [138]
In the citing paper
“Eszopiclone is the active isomer of zopiclone but binds preferentially to the α-3 benzodiazepine GABA receptor subtype, which might underpin its particular therapeutic profile. 33”
Citations
Cites
Insomnia: Definition, Prevalence, Etiology, and Consequences
Roth, T. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26929 · Cited by 1,492
GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain
Pirker, S., Schwarzer, C., Wieselthaler, A., Sieghart, W., & Sperk, G. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00442-5 · Cited by 1,344
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Jansson-Fröjmark, M., & Lindblom, K. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.10.016 · Cited by 646 · cited 1×
“(2006); Krystal et al. (2008); Walsh et al.”
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 2×
“, 2007), and enhance cognition, learning and memory in rodents (Collinson et al., 2002; Dawson et al., 2006).”
BackgroundMeta-analysis of benzodiazepine use in the treatment of insomnia.
(2000) · PubMed Central · Cited by 613
Sivertsen, B., Omvik, S., Pallesen, S., Bjorvatn, B., Havik, O. E., Kvale, G., Nielsen, G. H., & Nordhus, I. H. (2006) · JAMA · doi:10.1001/jama.295.24.2851 · Cited by 589 · cited 1×
“Racemic zopiclone reduces sleep latency and increases total sleep time (TST) (Ngen and Hassan, 1990; Ponciano et al., 1990; Noble et al., 1998; Sivertsen et al., 2006) (Table 6).”
Background
Research works printed but not linked: 18
- Brunello N., Abstract Presented at the World Psychiatric Association International Congress (WPA-Florence)
- Fava M., Presented at 46th Annual Meeting of the American College of Neuropsychopharmacology
- Fava M., Presented at the American Psychiatric Association (APA) 161st Annual Meeting
- Harrison NL, 2007, J Clin Psychia, 68, 6
- Holbrook AM, 2000, Can Med Ass J, 162, 225
- Isawa S., 2000, Nihon Shinkei Seishin Yakurigaku Zasshi, 20, 61
- Krystal A., 2008, Euro Neuropsychopharmacol, 18, S517
- Krystal A., 2008, Eur Neuropsychopharmacol, 18, S517
- Krystal AD, 2007, Journal of Clinical Sleep Medicine, 3, 48
- Meda Pharmaceuticals, 2008, Sonata SPC (online)
- Ponciano E., 1990, Int Clin Psychopharmacol, 5, 69
- Roth T., 2007, Journal of Clinical Sleep Medicine, 3, S7
- Sanofi-Aventis., 2007, Ambien (Zolpidem Tartrate) Tablets for Oral Administration Prescribing Information
- Sanofi Aventis, 2008, Stilnoct SPC
- Sanofi-Aventis, 2008, Zimovane SPC
- Scharf MB, 1994, J Clin Psychiat, 55, 192
- Sepracor., 2007, Lunesta (Eszopiclone) Tablets Prescribing Information
- Vermeeren A., 2002, Sleep, 25, 224
Cited by
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Self-citationThe GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00878-9 · Cited by 446
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Metadata
- Authors
- Nutt, D. J., & Stahl, S. M.
- Affiliations
- Imperial College London (GB)
- University of California San Diego (US)
- Corresponding author
- Nutt, David J
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-11-26
- Volume
- 24
- Issue
- 11
- Pages
- 1601-1612
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2008821456
- Cited by
- 163
- References
- 98
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 6 · 2014: 22 · 2013: 14 · 2012: 15
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Keywords
- GABA-A receptor modulators, Z-drugs, hypnotics, insomnia, zaleplon, zolpidem, zopiclone, eszopiclone, selective serotonin reuptake inhibitors, psychiatric comorbidity, GABAA receptor subtypes, alpha1 subunit, alpha2 subunit, alpha3 subunit, functional selectivity, pharmacokinetics, sedative effects, anxiolytic effects, antidepressant effects, drug tolerability
- MeSH terms
- Clinical Trials as Topic, Drug Therapy, Combination, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Receptors, GABA-A, Sleep, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics. https://app.cochat.ai/papers/10.1177/0269881109106927
- The paper
- Nutt, D. J., & Stahl, S. M. (2010). Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics. Journal of Psychopharmacology. https://doi.org/10.1177/0269881109106927
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.